Surgical endoscopy · 2025
Comparison of endoscopic papillectomy and pancreatoduodenectomy for high-grade intraepithelial neoplasia of the duodenal papilla: a retrospective cohort study.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Yuan, Wang Zhengwang, Chen Yuanyuan, Zhang Ke, Ge Xinyu, Zhu Jie, Wang Peng, Xu Qingcheng, Deng Denghao, Liu Jun, Xu Xiaolan, Chen Juan, Bai Dousheng, Xu Peng, Yao Jie
Аннотация
AIM: The objective of this study is to compare the clinical outcomes of endoscopic papillectomy (EP) and pancreatoduodenectomy (PD) for high-grade intraepithelial neoplasia of the duodenal papilla (HGIN-DP) and develop a preoperative risk prediction model for pathological upgrading.
METHODS: Retrospective analysis of 92 patients (43 EP vs. 49 PD) treated between 2014 and 2023. Propensity score matching (1:1) balanced baseline characteristics, yielding 62 matched cases. Univariate and multivariate logistic regression analysis identified risk factors for pathological upgrading. A nomogram was developed and validated using patient data.
RESULTS: PD demonstrated superior 5-year overall survival (88.5% vs. 61.2%, P < 0.05) but longer operative time (230.0 vs. 41.0 min), higher blood loss (250.0 vs. 1.0 mL), prolonged hospitalization (27.0 vs. 8.0 days), increased costs (CNY 71,116.0 vs. 25,898.0), and higher delayed gastric emptying rates (35.5% vs. 3.2%) compared to EP. Postoperative pathological upgrading occurred in 51.2% (EP) and 69.4% (PD) of cases. Among them, 29.0% were diagnosed with adenocarcinoma in the EP group and 38.7% in the PD group. Multivariate analysis identified age (OR = 1.11), platelet count (OR = 1.02), and tumor size > 1 cm (OR = 21.79) as risk factors for pathological upgrading. A nomogram incorporating these predictors showed strong discriminative accuracy (AUC = 0.91 training, 0.86 validation).
CONCLUSION: EP offers advantages in recovery and cost, while PD remains preferable for HGIN-DP patients with high-risk features. The validated prediction model aids preoperative risk stratification, guiding personalized treatment decisions.
METHODS: Retrospective analysis of 92 patients (43 EP vs. 49 PD) treated between 2014 and 2023. Propensity score matching (1:1) balanced baseline characteristics, yielding 62 matched cases. Univariate and multivariate logistic regression analysis identified risk factors for pathological upgrading. A nomogram was developed and validated using patient data.
RESULTS: PD demonstrated superior 5-year overall survival (88.5% vs. 61.2%, P < 0.05) but longer operative time (230.0 vs. 41.0 min), higher blood loss (250.0 vs. 1.0 mL), prolonged hospitalization (27.0 vs. 8.0 days), increased costs (CNY 71,116.0 vs. 25,898.0), and higher delayed gastric emptying rates (35.5% vs. 3.2%) compared to EP. Postoperative pathological upgrading occurred in 51.2% (EP) and 69.4% (PD) of cases. Among them, 29.0% were diagnosed with adenocarcinoma in the EP group and 38.7% in the PD group. Multivariate analysis identified age (OR = 1.11), platelet count (OR = 1.02), and tumor size > 1 cm (OR = 21.79) as risk factors for pathological upgrading. A nomogram incorporating these predictors showed strong discriminative accuracy (AUC = 0.91 training, 0.86 validation).
CONCLUSION: EP offers advantages in recovery and cost, while PD remains preferable for HGIN-DP patients with high-risk features. The validated prediction model aids preoperative risk stratification, guiding personalized treatment decisions.